Ptc Therapeutics (PTCT) Common Equity (2012 - 2026)

Ptc Therapeutics' Common Equity history runs 15 years deep, the most recent figure standing at -$180.5 million for Q1 2026.

• In Q1 2026, Common Equity rose 2.85% year-over-year to -$180.5 million; the TTM figure through Mar 2026 stood at -$180.5 million (up 2.85% YoY), while the FY2025 annual figure was -$205.3 million, up 81.3% from the prior year.
• Common Equity was -$180.5 million for Q1 2026 at Ptc Therapeutics, up from -$205.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$90.6 million in Q1 2022 to a low of -$1.1 billion in Q4 2024.
• Historically, Common Equity has averaged -$490.2 million across 5 years, with a median of -$347.1 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Common Equity slumped 24236.72% in 2022, then jumped 85.23% in 2025.
• A 5-year view of Common Equity shows it stood at -$347.1 million in 2022, then plunged by 135.84% to -$818.6 million in 2023, then plunged by 34.15% to -$1.1 billion in 2024, then soared by 81.3% to -$205.3 million in 2025, then increased by 12.1% to -$180.5 million in 2026.
• The last three Common Equity figures came in at -$180.5 million (Q1 2026), -$205.3 million (Q4 2025), and -$155.8 million (Q3 2025), per Business Quant data.